RNA Vaccine
Showing 1 - 25 of 9,751
COVID-19 Virus Infection, Ovarian Function Insufficiency, Fertility Disorders Trial in Istanbul (sars cov 2 biontec vaccine)
Enrolling by invitation
- COVID-19 Virus Infection
- +3 more
- sars cov 2 biontec vaccine
-
Istanbul, Gaziosmanpaşa, TurkeyGaziosmanpasa Training and Research Hospital
Aug 3, 2022
Shingles, Herpes Zoster Infection, Human Trial (Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection,
Not yet recruiting
- Shingles
- +2 more
- Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
- +6 more
- (no location specified)
Jan 19, 2023
SARS-CoV-2 Infection, COVID-19 Trial in Sumida-ku, Fukuoka (BNT162b2, Placebo)
Completed
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2
- Placebo
-
Sumida-ku, Tokyo, Japan
- +1 more
Jan 13, 2023
SARS-CoV-2 Trial in Salvador (Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine, Cohort 2 RNA VACCINE MCTI CIMATEC
Recruiting
- SARS-CoV-2
- Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine
- +3 more
-
Salvador, Bahia, BrazilHospital da Bahia
Mar 23, 2022
COVID-19 Vaccines Trial in Ho Chi Minh City, Ha Noi (ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine, Placebo (normal saline),
Active, not recruiting
- COVID-19 Vaccines
- ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
- +2 more
-
Ho Chi Minh City, Ho Chi Minh, Vietnam
- +2 more
Mar 14, 2022
COVID-19 Trial (Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Not yet recruiting
- COVID-19
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
- +3 more
- (no location specified)
Dec 22, 2022
Malaria Trial (BNT165e, Placebo)
Not yet recruiting
- Malaria
- BNT165e
- Placebo
- (no location specified)
Sep 29, 2023
Pulmonary Osteosarcoma Trial (RNA-LP vaccine)
Not yet recruiting
- Pulmonary Osteosarcoma
- RNA-LP vaccine
- (no location specified)
Jan 25, 2023
Influenza, Human Trial in Brisbane (ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine
Not yet recruiting
- Influenza, Human
- ARCT-2138
- +2 more
-
Brisbane, Queensland, AustraliaNucleus Network Brisbane Clinic
Nov 8, 2023
COVID-19, COVID-19 Vaccine Trial (RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca)
Not yet recruiting
- COVID-19
- COVID-19 Vaccine
- RNA MCTI CIMATEC HDT 5µg
- +3 more
- (no location specified)
Sep 13, 2022
Carcinoma, Squamous Cell, Head and Neck Tumor, Cervical Tumor Trial in Southampton (BNT113)
Recruiting
- Carcinoma, Squamous Cell
- +3 more
-
Southampton, Hampshire, United KingdomUniveristy Hospitals Southampton NHS Foundation Trust
May 17, 2022
Advanced Solid Tumor Trial in Bengbu (RNA tumor vaccine, RNA tumor vaccine+Navuliumab)
Recruiting
- Advanced Solid Tumor
- RNA tumor vaccine
- RNA tumor vaccine+Navuliumab
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Mar 21, 2022
Trust Trial in San Mateo (RNA vaccine, 20% adoption rate, 40% adoption rate)
Completed
- Trust
- RNA vaccine
- +6 more
-
San Mateo, CaliforniaSurveyMonkey
Feb 4, 2022
Malaria Trial in Tempe, Knoxville, San Antonio (BNT165b1, Placebo)
Recruiting
- Malaria
- BNT165b1
- Placebo
-
Tempe, Arizona
- +2 more
Jan 12, 2023
Kidney Transplant Recipients Trial in Baltimore (mRNA-1273 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna))
Active, not recruiting
- Kidney Transplant Recipients
- mRNA-1273 vaccine (Pfizer/BioNTech)
- mRNA-1273 vaccine (Moderna)
-
Baltimore, MarylandJohns Hopkins Hospital
Oct 4, 2021
SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2 (Omi XBB.1.5))
Not yet recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2 (Omi XBB.1.5)
-
Dublin, California
- +14 more
Aug 10, 2023
SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1))
Recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b5 Bivalent (WT/OMI BA.2)
- BNT162b2 Bivalent (WT/OMI BA.1)
-
Anaheim, California
- +9 more
Aug 8, 2022
Monkeypox Trial (BNT166a, BNT166c)
Not yet recruiting
- Monkeypox
- BNT166a
- BNT166c
- (no location specified)
Aug 4, 2023
Covid-19, Protection Against COVID-19 Trial in Berlin, Mannheim (BNT162b3)
Completed
- Covid-19
- Protection Against COVID-19
- BNT162b3
-
Berlin, Germany
- +1 more
Jun 24, 2022
Influenza, Human, COVID-19 Trial in United States (bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV)
Recruiting
- Influenza, Human
- COVID-19
- bivalent BNT162b2 (original/Omi BA.4/BA.5)
- +2 more
-
Athens, Alabama
- +18 more
Dec 22, 2022
Adult Glioblastoma Trial in Gainesville (Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane
Recruiting
- Adult Glioblastoma
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
-
Gainesville, FloridaUF Health
Aug 30, 2022
Kidney Transplant Recipients, Liver Transplant Recipients Trial in United States (Pfizer-BioNTech COVID-19 Vaccine Booster,
Recruiting
- Kidney Transplant Recipients
- Liver Transplant Recipients
- Pfizer-BioNTech Bivalent COVID-19 Vaccine
- +3 more
-
San Diego, California
- +14 more
Oct 31, 2022
Corona Virus Disease 2019(COVID-19) Trial in Chengdu (0.3ml of mRNA vaccine)
Enrolling by invitation
- Corona Virus Disease 2019(COVID-19)
- 0.3ml of mRNA vaccine
-
Chengdu, ChinaWest China Second University Hospital
Oct 3, 2022
Host Genetic Factors Underlying Ebola Virus Disease Risk,
Completed
- Ebola Virus Disease
-
Kalkata, Liberia
- +3 more
Aug 18, 2022
Melanoma Trial in Germany (Lipo-MERIT)
Active, not recruiting
- Melanoma
- Lipo-MERIT
-
Frankfurt, Germany
- +3 more
Jan 5, 2023